1988 through 1998

Mr. Peter Katevatis, Chairman and CEO of Mediscience Technology, identified medical optics as a high potential area.

To pursue potential opportunities in this arena of technology, Mediscience Technology acquired Laser Diagnostics Instruments (LDI) and its seminal photonics patent, Method and Apparatus for Detecting Cancerous Tissue Using Visible Luminescence, from Dr. Robert Alfano.

Under the guidance of Mr. Katevatis, the company entered into a long-term research relationship with the City University of New York and Dr. Alfano (Distinguished professor of Science and Engineering, and director New York State Center for Advanced Technology for Ultra fast Materials and Lasers).

1988 through 1998

Mediscience Technology funded research at the City University, generating over 30 patents in the areas of tissue spectroscopy and optical imaging with applications in cancer detection.

The company also partnered with and/or conducted research at leading medical institutions including the National Cancer Institute (NCI), Memorial-Sloan Kettering Cancer Center, New York Hospital Cornell Medical Center, Yale University Department of OBGYN, and others. Its technology was validated in both pre-clinical and clinical testing, progressing to a focus on commercialization.

1998 through 2003

A research team, headed by Dr. Robert R. Alfano, at City College's Institute for Ultrafast Spectroscopy and Lasers (IUSL), developed a significantly more sensitive technique than conventional fluorescence Spectroscopy to detect cancerous bio-molecules and structures.

Named Stokes Shift Emission Spectroscopy, this method evolves from seminal work performed at the IUSL for the past two decades. Dr. Alfano affirmed, "this revolutionary breakthrough will make optical biopsy the new medical frontier for cancer diagnosis and other medical applications."

2004

Mediscience Technology enters into a project agreement for the development of cancer detection and diagnosis devices with the Research Foundation of the City University of New York.

As stated in a dramatic news release dated May 2, 2004:

" … this Project Agreement provides the Company with a clear path in its intent to commercialize the CD Ratiometer for detecting and diagnosing cancers of the cervix, mouth, esophagus and gastro intestinal tract and other potential applications that are compatible with current state of the art computer hardware and operating systems.We expect to have a completed device by November 30, 2004".

RF-CUNY completes production of the improved CD-Ratiometer instrument(s). Mediscience Technology seeks approval by the United States Food and Drug Administration (FDA) for marketing in the U.S.

RF-CUNY successfully applies its research and development to deliver an updated CD-Ratiometer, as well as associated technology for use in Mediscience Optical Biopsy, including the testing of the Mediscience CD-Ratiometer on ex vivo human tissue specimens.

Under the specific terms of the project agreement, Mediscience Technology is granted an exclusive world-wide license, with the right to grant sublicenses, to manufacture, use, or sell all patented imaging product technology for molecular detection of cancer and physiological change.